Nuwellis, Inc. (NUWE): Nasdaq/NYSE listing notice — Nuwellis (NUWE) receives Nasdaq minimum bid price deficiency notice; 180-day cure period until June 4, 2024

Nuwellis, Inc.

Closing bid price below $1.00 for 30 consecutive trading days triggered Nasdaq deficiency notice on Dec 7, 2023.
Cure period ends June 4, 2024; must close at $1.00 or higher for 10 consecutive trading days to regain compliance.
If not cured by June 4, may qualify for second 180-day period if meeting other listing standards and notifying intent to cure.
Company considering options including reverse stock split; delisting risk remains if not compliant.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Nuwellis, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 7, 2023, Nuwellis, Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Marketplace Rule 581

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Nuwellis, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-057477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.